用于前列腺癌诊疗的PSMA靶向放射性小分子探针研究进展  

Research progress of PSMA-targeted radioactive small molecular probes for the diagnosis and treatment of prostate cancer

作　　者：谢佺 周雨萱 蔡舒玥 彭莹[2] 邱玲 林建国[1,2] XIE Quan;ZHOU Yuxuan;CAI Shuyue;PENG Ying;QIU Ling;LIN Jianguo(School of Pharmacy,Nanjing Medical University,Nanjing 211166;Jiangsu Institute of Nuclear Medicine,NHC Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Wuxi 214063,China)

机构地区：[1]南京医科大学药学院,江苏南京211166 [2]江苏省原子医学研究所,国家卫生健康委员会核医学重点实验室,江苏省分子核医学重点实验室,江苏无锡214063

出　　处：《南京医科大学学报(自然科学版)》2025年第1期105-110,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(22076069)。

摘　　要：前列腺癌是全球男性最常见的恶性肿瘤之一,严重危害男性身体健康。自前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)被证实是诊断前列腺癌的首选标志物,PSMA靶向放射性药物在前列腺癌诊治中取得显著进展,有效提高了前列腺癌的诊断灵敏度与治疗效果。文章就近年来PSMA靶向放射性分子探针的相关研究进展进行综述,分析探针结构设计理念并总结临床经验,以期对前列腺癌放射性诊疗分子探针的开发有所裨益。Prostate cancer is one of the most common malignant tumors among men worldwide,posing a significant threat to male health.Since prostate-specific membrane antigen(PSMA)has been proved to be the preferred biomarker for the diagnosis of prostate cancer,PSMA-targeted radiopharmaceuticals have made significant progress in the diagnosis and therapy of prostate cancer,effectively improving the diagnostic sensitivity and treatment effect of prostate cancer.This article reviews the research progress of PSMA-targeted radioactive molecular probes in recent years,analyzes the design concepts of probe structure and summarizes the clinical experience.It is expected to benefit the development of radioactive molecular probes for diagnosis and treatment of prostate cancer.

关 键 词：前列腺癌 前列腺特异性膜抗原 分子探针 诊断 治疗 

分 类 号：R737.25[医药卫生—肿瘤]